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Abstract
Background: Retinoid therapy is widely employed in clinical oncology to differentiate malignant cells into their
more benign counterparts. However, certain high-risk cohorts, such as patients with MYCN-amplified
neuroblastoma, are innately resistant to retinoid therapy. Therefore, we employed a precision medicine approach to
globally profile the retinoid signalling response and to determine how an excess of cellular MYCN antagonises
these signalling events to prevent differentiation and confer resistance.
Methods: We applied RNA sequencing (RNA-seq) and interaction proteomics coupled with network-based systems
level analysis to identify targetable vulnerabilities of MYCN-mediated retinoid resistance. We altered MYCN
expression levels in a MYCN-inducible neuroblastoma cell line to facilitate or block retinoic acid (RA)-mediated
neuronal differentiation. The relevance of differentially expressed genes and transcriptional regulators for
neuroblastoma outcome were then confirmed using existing patient microarray datasets.
Results: We determined the signalling networks through which RA mediates neuroblastoma differentiation and the
inhibitory perturbations to these networks upon MYCN overexpression. We revealed opposing regulation of RA and
MYCN on a number of differentiation-relevant genes, including LMO4, CYP26A1, ASCL1, RET, FZD7 and DKK1.
Furthermore, we revealed a broad network of transcriptional regulators involved in regulating retinoid responsiveness,
such as Neurotrophin, PI3K, Wnt and MAPK, and epigenetic signalling. Of these regulators, we functionally confirmed
that MYCN-driven inhibition of transforming growth factor beta (TGF-β) signalling is a vulnerable node of the MYCN
network and that multiple levels of cross-talk exist between MYCN and TGF-β. Co-targeting of the retinoic acid and
TGF-β pathways, through RA and kartogenin (KGN; a TGF-β signalling activating small molecule) combination
treatment, induced the loss of viability of MYCN-amplified retinoid-resistant neuroblastoma cells.
Conclusions: Our approach provides a powerful precision oncology tool for identifying the driving signalling networks for
malignancies not primarily driven by somatic mutations, such as paediatric cancers. By applying global omics approaches
to the signalling networks regulating neuroblastoma differentiation and stemness, we have determined the pathways
involved in the MYCN-mediated retinoid resistance, with TGF-β signalling being a key regulator. These findings revealed a
number of combination treatments likely to improve clinical response to retinoid therapy, including co-treatment with
retinoids and KGN, which may prove valuable in the treatment of high-risk MYCN-amplified neuroblastoma.
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Background
The paediatric cancer neuroblastoma arises when neur-
onal stem cells of a transient embryonal tissue, the neural
crest, fail to complete their terminal differentiation into
neurons of the peripheral nervous system and instead
transform to become oncogenic [1, 2]. This failure of an
embryonal population of neuroblasts to differentiate is
largely due to the aberrant maintenance of stemness sig-
nals arising from genetic and epigenetic lesions [3–7].
Therefore, neuroblastoma has been termed a malignancy
which is due to a differentiation block [8, 9], with tumours
consisting of more stem-like cells representing more
aggressive and high-risk disease [10, 11]. Interestingly,
neuroblastoma has the highest rate of spontaneous regres-
sion of any solid tumour [12–15], which is thought to be
due to the late restoration of normal developmental sig-
nalling resulting in tumour cell differentiation or apop-
tosis. Thus, even neuroblastomas with metastatic spread
(stage 4S) can have a good prognosis due to spontaneous
regression, especially in infants below 18 months of age
[16, 17]. By contrast, neuroblastomas diagnosed later than
18 months or those with amplification of the MYCN
oncogene have much worse prognosis. In fact, neuroblast-
oma accounts for 15% of all childhood cancer deaths, the
highest of any solid tumour [16]. The survival rate of the
high-risk neuroblastoma patients has not improved in
decades, remaining steady at a 5-year survival of 40–50%
[18]. Therefore, it is a clinical imperative that effective
therapeutics for high-risk neuroblastoma be identified.
Differentiation therapy is widely employed in clinical can-
cer treatment [19–26] as both primary and maintenance
therapies. Retinoid-induced differentiation of neuronal pre-
cursors is a successful treatment strategy for low and
intermediate risk neuroblastoma patients. Both all-trans-
retinoic acid (ATRA, tretinoin) and 13-cis-retinoic acid
(isotretinoin) are used in neuroblastoma therapy with iso-
tretinoin being the preferred compound [20–22, 24, 27, 28].
However, despite the effectiveness of retinoid treatment for
some patients, it is ineffective for many high-risk patients
[24, 29]. This is largely due to MYCN-induced resistance to
retinoid therapy [24]. MYCN is a primarily neuronal-
specific member of the MYC proto-oncogene family. It is
expressed during normal neural crest development, and
when under normal regulation it does not prevent terminal
differentiation of neuroblasts [30, 31]. However, amplified
MYCN prevents neuronal differentiation [32, 33], and aber-
rant MYCN signalling alone is sufficient to induce neuro-
blastoma in animal models [2, 34]. MYCN amplification
occurs in over 20% of neuroblastoma and contributes to
metastasis and chemoresistance [17, 35]. Additionally, 50%
of neuroblastoma patients who initially respond to retinoic
acid (RA) therapy develop retinoid resistance [8]. However,
despite the variability of the clinical response to RA, there
is a lack of recurrent somatic mutations in components of
the RA signalling pathway [3, 36], suggesting adaptor
mechanisms conveying resistance. Furthermore, epigenetic
regulation has been shown to block neuronal precursor
differentiation [37]. Therefore, rather than focussing on
mutations or epigenetic status, we employed RNA-seq and
network-based analysis to globally profile the functional
status of gene regulatory networks in response to RA.
Analysis at this level captures the functional effects of all
upstream regulatory alterations regardless of their origin
(e.g. mutations, transcriptional and epigenetic alterations,
miRNA/lncRNA-mediated regulation). Such approaches
are particularly pertinent for paediatric cancers as they have
a low rate of genetic mutation compared with adult can-
cers, and accordingly present far fewer actionable genetic
alterations [38]. The only actionable mutation in neuro-
blastoma is mutant ALK, but even this gene is mutated in
only 9.2% of tumours [3, 38].
While elevated MYCN levels inhibit RA-mediated
neuronal differentiation [32, 33], the precise molecular
mechanisms are unknown. Elucidating these mecha-
nisms could reveal potential targets and combination
treatments that can re-sensitise MYCN-amplified cells
to retinoid therapy. To this end, we transcriptionally
profiled (RNA-seq) ATRA (from here on referred to as
RA) exposed neuroblastoma cells in the presence of high
and low MYCN expression levels and performed
network-based precision medicine analysis [38–41].
Additionally, we profiled changes in the MYCN protein–
protein interactome in response to RA. We thereby
identified how MYCN globally modulates the differenti-
ation response and identified network nodes which can
be therapeutically targeted to prevent amplified MYCN
from inhibiting the RA-induced differentiation of neuro-
blastoma cells.
Methods
Cell culture and inhibitor treatments
The cell line SH-SY5Y/6TR(EU)/pTrex-Dest-30/MYCN
(SY5Y-MYCN) stably expresses a tetracycline-inducible
MYCN expression vector and was kindly provided by
the Westermann lab [42–44]. Cells were cultured in
RPMI 1640 (Gibco) supplemented with 10% fetal bovine
serum (Gibco), 2 mM L-glutamine (Gibco) and 1%
penicillin-streptomycin solution (Gibco). RA (Sigma-Al-
drich) was given at a final concentration of 1 μM, to in-
duce differentiation. Kartogenin (Selleck) was dissolved
in DMSO and used in concentrations ranging from 0.1–
20 μM. RepSox (Selleck) was dissolved in DMSO and
used in concentrations ranging from 1–100 nM. For ve-
hicle controls equivalent volumes of DMSO were added
to cells. Doxycycline (Dox; Sigma) dissolved in water
was used at a final concentration of 1 μg/ml to in-
duce MYCN expression in SY5Y-MYCN. Dox was
replenished every 24 h for any treatment longer than a
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24 h duration. For Dox co-treatments cells were pre-
incubated with doxycycline for 24 h before addition of RA
and had fresh doxycycline given at the start of RA treat-
ment. Cells were imaged using an Olympus CKX41
microscope.
Western blot and quantitative RT-PCR
Western blotting and quantitative RT-PCR (RT-qPCR)
were performed as previously described [45]. Antibodies
used were TrkB (1/1,000 dilution, #4603, Cell Signaling
Technologies) and ERK1/2 (1/10,000 dilution, M5670,
Sigma Aldrich). TaqMan assays (Applied Biosystems) used
were DKK1 (Hs00183740_m1*), EGR1 (Hs00152928_m1*),
FZD7 (Hs00275833_s1*), RET (Hs01120030_m1*), NTRK2
(Hs00178811_m1*), c-MYC (Hs00905030_m1*), MYCN
(Hs00232074_m1*), ASCL1 (Hs04187546_g1), LMO4
(Hs01086790_m1) and the endogenous control genes
RPLPO (4310879E) and ACTB (β-actin, 4326315E). Bio-
logical duplicates were generated for all samples; technical
replicates for every sample were also performed.
mRNA sequencing and bioinformatics analysis
SY5Y-MYCN cells were exposed to one of four treatments
(24 h DMSO, 24 h RA, 24 h RA and 48 h Dox and 48 h
Dox), with biological duplicates. While the 48-h Dox-only
sample was also previously analysed as part of a MYCN
overexpression time-course [42], analysis of the RA sam-
ples and their comparison with the 48-h Dox only samples
has not previously been published. The 48-h Dox
treatment was performed and the samples were sequenced
together with the DMSO, RA-only and RA and Dox sam-
ples. Total mRNA was extracted using TRI Reagent
(Sigma-Aldrich) according to the manufacturer’s protocol,
and DNA was digested with RQ1 RNase free DNase (Pro-
mega). RNA quality was checked by RT-qPCR (as above)
and on a 2100 Bioanalyzer (Agilent) using a Eukaryote
Total RNA Nano Chip (version 2.6). All samples had a
RIN value in the range of 8.40–9.20. Sequencing libraries
were generated from 2 μg of total RNA per sample with a
TruSeq RNA sample preparation Kit v2 (Illumina) accord-
ing to the manufacturer’s protocol. Size and purity of the
libraries were analysed on a Bioanalyzer High Sensitivity
DNA chip (Agilent). Libraries were clustered using
TruSeq Single-Read Cluster Kit v5-CS-GA (Illumina) and
sequenced on an Illumina Genome Analyzer IIx with a
TruSeq SBS Kit v5-GA (Illumina).
The sequence reads were analysed as described previ-
ously [45]. Differentially expressed genes were called using
general linear models in edgeR [46]. P values were adjusted
for multiple testing with the Benjamini–Hochberg correc-
tion and a corrected P cutoff of 0.05 was used. To make the
absolute expression levels of genes comparable with each
other, the read counts per million were adjusted by gene
length in kilobases (CPMkb). The mRNA-seq data were
deposited in ArrayExpress (http://www.ebi.ac.uk/arrayex-
press) under accession number E-MTAB-2689.
Additional software tools
Ingenuity Pathway Analysis (IPA) software was also used
for the inferred transcriptional regulator (ITR), pathway
and gene ontology (GO) analysis. String (http://www.string-
db.org/) was used to generate protein–protein interaction
networks, and the KEGG pathway enrichment analysis tool
in String was also applied to these networks. Area-
proportional Venn diagrams were generated using BioVenn
(http://www.cmbi.ru.nl/cdd/biovenn/) and four-way com-
parisons were generated using Venny (http://bioinfogp.c
nb.csic.es/tools/venny/index.html). Measurements of neur-
ite length and cell width were obtained from images using
ImageJ v1.44p (http://imagej.nih.gov/ij).
Proteomics
Mass spectrometry-based interaction proteomics were
conducted on SY5Y-MYCN (un-induced, 48-h MYCN
overexpression, 24-h 1-μM RA treatment and 48-h MYCN
overexpression and 24-h 1-μM RA co-treatment) for the
MYCN protein. Interaction proteomics were performed as
previously described [47]. MYCN was immunoprecipitated
by using Protein A/G PLUS-agarose beads (sc-2003, Santa
Cruz) conjugated to MYCN antibody (1/1,000 dilution,
sc-53993, Santa Cruz) or IgG. Three biological and two
technical replicates were performed per condition.
Cell viability assay
Cell viability was analysed by MTS assay as described [45],
with values normalised to untreated control cells. The re-
sults represent the mean ± standard deviation of triplicate
biological replicates, expressed as a percentage of control.
Results
MYCN overexpression inhibits RA-induced neuronal
differentiation
SY5Y neuroblastoma cells treated with RA undergo neur-
onal differentiation to become dopaminergic neurons [45,
48–51]. We profiled global transcriptional changes mediated
by RA in the MYCN Dox-inducible SY5Y-MYCN cell line,
which was previously generated from the parental SY5Y cell
line by the Westermann lab [42–44]. To assess the effect of
MYCN overexpression on neuronal differentiation we im-
aged SY5Y-MYCN cells treated with RA while overexpres-
sion of the MYCN transgene was either induced or un-
induced (Fig. 1a). A differentiation ratio for each treatment
group was then calculated by dividing the length of the lon-
gest axon of a cell by the cell’s width. Like SY5Y cells, SY5Y-
MYCN cells underwent RA-mediated differentiation in the
absence of MYCN induction. However, when MYCN ex-
pression was induced (reaching 10–15 times higher levels
than in un-induced cells; Additional file 1: Figure S1a) the
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Fig. 1 (See legend on next page.)
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ability of RA to efficiently differentiate these cells strongly
and significantly was attenuated (t-test, RA versus RA and
Dox p < 0.0001). While endogenous MYCN mRNA (paren-
tal SY5Y cells) expression was downregulated by RA treat-
ment, ectopic MYCN in SY5Y-MYCN cell lines was not
reduced as it is not under the control of the endogenous
MYCN promoter (Additional file 1: Figure S1b; also see
Duffy et al. [45]). Confirming that the RA was active, it re-
duced the expression of endogenous c-MYC mRNA by a
similar extent in both SY5Y and un-induced SY5Y-MYCN
cell lines (Additional file 1: Figure S1b).
MYCN overexpression antagonises the normal
transcriptional response to RA treatment
The mechanisms through which MYCN blocks RA-
mediated neuronal differentiation are highly relevant to
MYCN-amplified neuroblastoma patients, who generally
do not respond well to retinoid treatment [20, 27]. There-
fore, to identify these mechanisms we conducted mRNA-
seq of SY5Y-MYCN cells under four treatment conditions:
(i) 24-h DMSO (control), (ii) 24-h RA, (iii) 24-h RA and
48-h Dox, and (iv) 48-h Dox. Firstly, we confirmed that a
number of the genes encoding the RA receptors, which are
required to facilitate cellular responsiveness to RA, were
expressed in SY5Y-MYCN cells (Additional file 1: Figure
S1c). Of these the expression of both RARA and RARB
was upregulated upon RA treatment. In total, between 511
and 839 differentially expressed (DE) genes were detected
per treatment group, with a high degree of overlap between
the co-treatment (RA and Dox) sample and the individual
treatments (Fig. 1b; Additional file 2: Table S1; Additional
file 3: Table S2; Additional file 4: Table S3; Additional file 5:
Table S4). MYCN overexpression predominantly downreg-
ulated gene expression as we have previously described
[42], while RA treatment produced a very similar number
of up- and downregulated DE genes (Fig. 1c). While there
was a trend for the greatest fold changes to occur in genes
which had lower pre-treatment expression states, genes
across the full range of pre-treatment expression levels
were differentially expressed (Fig. 1d).
Of the 169 genes regulated in common between MYCN
overexpression and RA treatment, 95 were regulated in op-
posing directions (up- or downregulated) by each treatment
(Fig. 2a). These differentially activated genes are likely key
to MYCN’s ability to block RA-mediated neuronal differen-
tiation and contain both known and novel components of
differentiation signalling (see below). To validate the accur-
acy of the RNA-seq analysis we analysed the changes in ex-
pression (by qPCR) of MYCN (Additional file 1: Figure
S1a) and seven selected genes, RET, DKK1, EGR1, FZD7,
ASCL1, LMO4 and c-MYC (Fig. 2b), which were identified
as being DE in the RNA-seq data. The results confirmed
the reliability of the RNA sequencing data (Fig. 2b;
Additional file 1: Figure S1a). The qPCR also confirmed the
differing direction of regulation for RET, FZD7, EGR1,
ASCL1 and LMO4 between the RA treatments and MYCN
induction (Fig. 2b). To eliminate any Dox-related, non-
MYCN-dependent, role in the expression changes of these
genes we treated parental SY5Y cells with Dox. Dox treat-
ment in SY5Y cells did not reproduce the expression changes
observed when MYCN was overexpressed in SY5Y-MYCN
cells via Dox treatment (Additional file 1: Figure S1d).
We also confirmed by qPCR and western blotting the
strong induction of the BDNF receptor NTRK2 (TrkB) upon
RA treatment, which was revealed in the RNA-seq results
(Additional file 1: Figure S1e, f). This RA-mediated induction
of NTRK2 was sustained, and indeed continued to rise over
longer RA treatments (Additional file 1: Figure S1e, f). While
high NTRK2 expression combined with amplified MYCN is
a marker for high-risk neuroblastoma [52], NTRK2 pathway
activation by BDNF ligand treatment is also known to aid
RA-mediated differentiation [53]. Our results indicate that
RA dramatically upregulates NTRK2 expression, potentially
priming the cells to respond to BDNF signalling.
Transcriptome-wide profiling reveals novel regulatory
mechanisms of known differentiation-associated genes
Of the genes regulated in opposing directions by RA and
MYCN (Fig. 2a), we examined three in more detail:
CYP26A1, LMO4 and ASCL1 (Fig. 2c). These genes were
(See figure on previous page.)
Fig. 1 MYCN overexpression antagonises RA-induced differentiation of neuroblastoma cells at the transcriptional level. a SY5Y-MYCN cells treated
for the following time-periods: 1 μl/ml DMSO for 3 days, 1 μg/ml Dox (to induce MYCN expression) for 4 days, 1 μM RA for 3 days or combination
treatment 1 μg/ml Dox for 4 days and 1 μg/ml RA for 3 days. Left: Imaging of the SY5Y-MYCN cells. All panels are imaged at 40× magnification.
Right: The differentiation ratio of cells treated with individual agents or combination treatments was calculated by dividing the length of the
longest axon of a cell by the cell’s width. The images from three biological replicates were pooled, and then measurements of individual cells
were made using ImageJ v1.44p (http://imagej.nih.gov/ij). The range of measured cells (N) per treatment group is 150–259. The differentiation
ratio of each cell was then calculated by dividing the length of its longest axon by the cell’s width. The p value for each treatment group
compared with untreated control cells (t-test) is shown above each treatment box. b Number and overlap of differentially expressed (DE) genes
in each treatment group, as detected by RNA-seq. The area-proportional Venn diagram was generated using BioVenn (http://www.cmbi.ru.nl/cdd/
biovenn/) [123] and shows the overlap between the genes DE in each treatment group compared to the untreated control cells. c Proportions of
up- and downregulated DE mRNAs for each treatment group when compared with untreated SY5Y-MYCN cells, as detected by RNA-seq. d All
significant DE genes (RNA-seq), with expression level in the control state (no RA and un-induced MYCN) plotted against the fold change after
treatment. Each significant DE gene is denoted by a purple dot
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selected as they have previously been associated with
either neuronal differentiation, MYCN or neuroblastoma,
but our analysis reveals their opposing transcriptional
regulation by RA and MYCN. Our RNA-seq analysis re-
vealed that the expression of the CYP26A1 gene was
massively increased upon RA treatment, jumping from
almost undetectable to highly expressed (0.05–36.59
CPMkb; Fig. 2c). This increase was further enhanced by the
combination of RA and Dox, despite Dox alone slightly
reducing CYP26A1 expression (Fig. 2c). CYP26A1 is a
member of the cytochrome P450 family and is involved in
a negative feedback loop, where RA activates its expression
while the CYP26A1 protein inactivates RA by hydroxyl-
ation [54–58]. CYP26A1 also regulates the production of
migratory cranial neural crest cells [59]. Our data show a
trend for MYCN overexpression to enhance the RA-
induced expression of the RA inhibitor CYP26A1 (Fig. 2c).
LMO4 is a transcriptional regulator involved in the
epithelial-to-mesenchymal transition of neuroblastoma
and neural crest cells [60]. It can also inhibit differenti-
ation of mammary epithelial cells and is overexpressed in
breast cancer [61]. Its paralogue, LMO1, is a neuroblast-
oma oncogene which is duplicated in 12.4% of tumours,
and is associated with aggressive disease [62]. LMO4 in-
terferes with neuritogenesis in SY5Y cells [63], has a role
in the differentiation of progenitor cells of motor neurons
and the cranial neural crest and is highly expressed in pro-
liferating mouse epithelial tissues [64, 65]. Our results re-
veal that LMO4 mRNA levels are upregulated by MYCN
and downregulated by RA, while in the combination treat-
ment MYCN overexpression partially reverses RA’s inhibi-
tory effects on LMO4 expression (Fig. 2c).
The ASCL1 transcription factor stimulates neuronal
differentiation, but its pro-differentiation functions are
blocked by MYCN at the protein level, where MYCN
maintains the phosphorylation of ASCL1 [9]. ASCL and
MYCN also share some of the same promoter targets,
but direct opposing regulation of these shared targets [66].
In addition to MYCN’s role in regulating phosphorylation
of the ASCL1 protein, our data revealed that MYCN over-
expression regulates ASCL1 mRNA levels (Fig. 2c).
MYCN overexpression increased the level of ASCL1
mRNA, while RA treatment strongly reduced it (Fig. 2c).
Combination treatment partially rescued the effect of RA
on ASCL1. Therefore, ASCL1 is another gene differen-
tially regulated by RA and MYCN overexpression, which
is likely to contribute to MYCN’s ability to block neuronal
differentiation.
In order to determine if the results obtained from the cell
line were relevant to neuroblastoma tumour biology, we
examined the effect of these genes on neuroblastoma pa-
tient survival in three large neuroblastoma tumour datasets
(Versteeg [67], SEQC [68] and Kocak [69], with 88, 498 and
649 tumours, respectively), using the R2: Genomics
Analysis and Visualization Platform (http://r2.amc.nl).
CYP26A1, LMO4 and ASCL1 mRNA expression levels
were each prognostic of patient outcome (Fig. 2d;
Additional file 1: Figure S1g), consistent across the three
datasets. Furthermore, the elevated expression of ASCL1
and LMO4 seen in the MYCN-overexpressing SY5Y-
MYCN cells matched the high expression of these genes in
the poor outcome tumours. Conversely, tumours with low
ASCL1 and LMO4 expression had better prognosis, match-
ing the cell line results in which these genes were downreg-
ulated by RA. The correlation between the RNA-seq and
the tumour data was not as straightforward for CYP26A1.
Expression of CYP26A1 was induced by RA and
augmented further by MYCN induction, but not by MYCN
induction alone (Fig. 2c). High levels of CYP26A1 were also
indicative of poor outcome. Thus, while not activated by
MYCN alone, CYP26A1 expression is induced by RA
treatment even more strongly in the presence of elevated
MYCN, and subsequently inactivates RA, resulting in
retinoid resistance.
To move beyond the single-gene level and identify
additional mechanisms through which MYCN overexpres-
sion can interfere with RA signalling we performed global
pathway and network-based analysis of the RNA-seq data.
(See figure on previous page.)
Fig. 2 Likely drivers of the MYCN-mediated differentiation block: genes regulated in opposing directions by RA treatment and MYCN overexpression. a
Number and overlap of the 169 differentially expressed genes (compared with control transcriptome) altered in opposing directions between the RA and
MYCN overexpression treatments. Left: Overlap of genes upregulated by RA (24 h) and downregulated by MYCN overexpression (48 h). Right: Overlap of
genes upregulated by MYCN overexpression (48 h) and downregulated by RA (24 h). The names of the genes which were common between the
treatments but differentially expressed in opposing directions are shown below each Venn diagram. Venn diagrams were generated using Venny (http://
bioinfogp.cnb.csic.es/tools/venny/index.html). b RT-qPCR validation in SY5Y-MYCN cells of the RNA-seq for a panel of differentially expressed genes, EGR1,
FZD7, RET, DKK1,c-MYC, ASCL1 and LMO4. Levels of expression for each gene are set relative to those in untreated samples of control cells. RT-qPCR time-
points mirror the RNA-seq time-points. RT-qPCR samples denoted by “qPCR“ with their RNA-seq counterparts denoted by “seq”. Error bars for qPCR samples
denote RQ Min and RQ Max, while for RNA-seq samples they are standard deviation. c Levels of absolute gene expression for CYP26A1 (left), ASCL1 (centre)
and LMO4 (right), in each of the SY5Y-MYCN RNA-seq treatments. Expression is in read counts per million adjusted by gene length in kilobases (CPMkb),
with error bars denoting the standard deviation between replicates. d Kaplan–Meier survival curves showing the predictive strength of the expression levels
of the CYP26A1 (left), ASCL1 (centre) and LMO4 (right) mRNAs in neuroblastoma tumours on patient outcome. Generated using the Kocak [69] 649
neuroblastoma tumour dataset in the R2: Genomics Analysis and Visualization Platform (http://r2.amc.nl)
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Global analysis of mRNA-seq results reveals MYCN and RA
differentially activate a range of transcriptional regulators
We analysed the RNA-seq data using the GO disease and
function terms tool of the IPA programme. Using existing
knowledge, GO term analysis identifies patterns of gene
regulation in the transcriptomic data which match pat-
terns related to biological events such as apoptosis,
ribosome biogenesis, proliferation and DNA replication.
GO term analysis confirmed the phenotypic observations,
showing that RA-activated genes are involved in neuronal
differentiation processes and RA-inhibited genes are
involved in cell movement (Fig. 3a). Conversely, MYCN
overexpression repressed differentiation-associated pro-
cesses, while combination treatment tended to fall be-
tween the two extremes but still with a bias towards the
repression of neuronal differentiation (Fig. 3a). Disease
and function GO analysis of the top 15 GO terms per con-
dition revealed that RA inhibited proliferation and cancer-
associated processes (Additional file 1: Figure S2a).
IPA analysis also showed that these phenotypic changes
were achieved by RA differentially regulating the compo-
nents of a number of signalling pathways associated with
neuronal differentiation, including RAR and VDR/RXR,
which were in the top 15 signalling pathways altered during
differentiation (Fig. 3b). In particular, the expression of
components of the RAR pathway itself were regulated by
RA at all levels when projected onto a RAR pathway map
(Fig. 3c). Aside from known RA-associated pathways, our
analysis highlighted that a large array of signalling pathways
participate in the differentiation of neurons, including
axonal guidance, protein kinase A, eNOS and G-protein
coupled receptor signalling (Fig. 3b).
The IPA suite was next used to identify the ITRs of DE
genes of each treatment condition. Given the wealth of
transcriptomic experiments publically available, a vast
database exists regarding how genes are transcriptionally
regulated in response to a wide array of regulators (genes,
proteins or chemical compounds). ITR analysis harnesses
this prior knowledge to identify patterns of transcriptional
regulation in our datasets which match the patterns pro-
duced by known regulators. This comparison of known
patterns versus patterns observed in the data enables the
inference of which regulators are likely responsible for the
differential gene expression seen in our transcriptomics
data. Given this prior knowledge, ITR analysis can not
only infer the regulators likely altering transcriptional
regulation but also predict their activation status, i.e.
whether these regulators were activated or inhibited in the
treatment groups compared to the control cells [42, 70].
For more information on the statistical algorithms
employed to match the detected changes in gene expres-
sion to known gene regulatory modules from the curated
IPA knowledge database see Krämer et al. [70]. RA itself
was a top ITR in each of the treatment groups (Fig. 4a, b).
The analysis correctly and independently predicted it to
be activated in both of the conditions in which RA treat-
ment was performed (24-h RA and 24-h RA and 48-h
Dox), providing a positive validation of the ITR analysis.
As previously shown [42], RA as an ITR was inhibited by
48-h Dox treatment (Fig. 4a, b), revealing that MYCN DE
regulates known RA target genes. Indeed, consistent with
MYCN repressing RA’s effects on its target genes, the acti-
vation z score of RA for the combination treatment (24-h
RA and 48-h Dox) was lower than for the 24-h RA single
treatment, despite both conditions receiving the same
dose and duration of RA treatment (Fig. 4a, b).
A clear trend emerged from the top ITRs of each
condition: RA primarily activated transcriptional regula-
tors (14/15) while MYCN primarily repressed them (12/
15) (Fig. 4b). This trend was also clear across the top 100
ITRs (Additional file 1: Figure S3a; Additional file 6: Table
S5). In line with this trend and the mutual antagonism of
RA and MYCN, the combination treatment showed an
almost equal number of ITRs to be activated and re-
pressed, (seven and eight, respectively). The top protein
ITRs of RA treatment formed a highly interconnected net-
work, revealing the complexity of the molecular mecha-
nisms involved in RA-mediated neuronal differentiation
(Fig. 4c). Interestingly, almost half of the 24-h RA ITRs
were chemical compounds, suggesting that additional
drugs, if co-administered, may be able to improve the dif-
ferentiation efficiency of clinical RA treatments.
Antagonistic regulation of transcriptional regulators
by RA and MYCN
To identify the transcriptional regulators through which
MYCN exerts its inhibition of RA treatment, we next exam-
ined transcriptional regulators which were differentially acti-
vated between the treatment groups. A number of the top
15 ITRs were differentially regulated between the RA and
MYCN overexpressing conditions, such as TGFB1, HIF1A,
APP and FGF2 (Fig. 4b). To identify all ITRs which were
differentially activated between RA and Dox treatments we
overlapped the ITRs and their activation/inhibition status
(Additional file 1: Figure S4a). Then, we generated protein
interaction maps to reveal the transcriptional regulator net-
works which are likely to mediate MYCN inhibition of
neuronal differentiation (Additional file 1: Figure S4a). The
RA-inhibited and MYCN-activated protein ITRs were
enriched for β-catenin binding genes (molecular function
GO analysis, p = 8.52E-07) and Wnt signalling-related genes
(KEGG pathway enrichment analysis, p= 4.84E-02), with all
of the Wnt-related proteins present being antagonists of the
pathway. Conversely, the protein–protein interaction net-
work for the ITRs activated by RA and inhibited by MYCN
overexpression were enriched for MAPK pathway-related
proteins (KEGG pathway enrichment analysis, p = 6.829E-
17). This network also included the WNT1 ITR, which
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combined with the results from the first network suggests
that RA activates WNT1 signalling and represses Wnt
antagonists. MYCN has the inverse effect, inhibiting WNT1
and activating Wnt antagonists. We have recently inde-
pendently shown that Wnt and MAPK signalling are in-
volved in regulating differentiation in MYCN-amplified
neuroblastoma cells [42, 71]. In SY5Y cells, which are
MYCN single-copy, the Wnt-RA cross-talk has been shown
to be mediated by PSEN1 (Presenilin 1) [72]. We previously
discovered novel cross-talk between the MYCN oncogene
and GSK3 (one of the Wnt-related ITRs) [45], β-catenin
[71] and MAPK [42]. Therefore, the protein–protein inter-
action network of regulators differentially activated by RA
and MYCN overexpression identified here confirm our pre-
vious findings, support the validity of the current analysis
and reveal that MYCN’s ability to inhibit RA-mediated dif-
ferentiation involves the regulation of Wnt and MAPK sig-
nalling components.
To identify novel ITRs which may enhance the clinical re-
sponse to RA when given as combination therapies, we next
collated ITRs which were strongly differentially regulated
between the three conditions (Fig. 4d). One of these regula-
tors was MYCN itself. The effects of MYCN overexpression
on known MYCN target genes predominated over RA ef-
fects, with MYCN overexpression strongly activating MYCN
target gene expression, an effect which was only mildly at-
tenuated by RA co-treatment (Fig. 4d). It should be noted,
however, that this was in a MYCN-inducible system where
MYCN expression was not under the control of its en-
dogenous promoter and enhancers. Although artificial, this
scenario mirrors highly amplified MYCN neuroblastoma
where over 70 additional copies of the MYCN gene can be
inserted in the tumour’s genome, often losing their endogen-
ous promoters and enhancers. Interestingly, the strongly dif-
ferentially regulated ITRs were significantly enriched for the
Neurotrophin signalling pathway (BDNF, NGF and Trk re-
ceptors etc., see 'MYCN overexpression antagonises the nor-
mal transcriptional response to RA treatment' section
above; KEGG p= 5.739E-10; Additional file 1: Figure S4b),
which is strongly associated with neuronal differentiation
and neuroblastoma outcome. These data suggest a conver-
gence of the molecular mode of action of RA and neurotro-
phin (NGF/BDNF) mediated differentiation. The most
highly connected nodes in the network included histone
deacetylases (HDACs), which have recently been shown to
synergise with RA treatment [8, 73–75], and TGFB1.
TGFB1 is a ligand of the transforming growth factor beta
(TGF-β) signalling pathway, with known roles in modulating
differentiation [76–79]. The TGFB1 ITR was strongly differ-
entially activated between RA and MYN overexpression
conditions; RA activated TGFB1 while MYCN overexpres-
sion strongly inhibited it (Fig. 4d). The effect of MYCN was
more dominant and TGFB1 activity was also inhibited in
the co-treatment (Fig. 4d). We therefore further assessed the
possibilities for TGFB1-informed therapy to enhance the re-
sponse of MYCN-amplified cells to retinoid therapy.
MYCN regulates TGFB1 and its target genes
To compare the effect of MYCN overexpression and RA
on TGFB1 with the effects of amplified MYCN, we next
examined sequencing datasets (RNA-seq and MYCN
ChIP-seq) which we had previously generated (ArrayEx-
press (http://www.ebi.ac.uk/arrayexpress/) accession num-
bers E-MTAB-2690, E-MTAB-2691, E-MTAB-1684, E-
MTAB-4100 and E-MTAB-2689) [42, 45, 71, 80]). These
datasets revealed that TGFB1 was also a top regulator of
the differences in the MYCN regulator and effector net-
works between single copy MYCN and MYCN-amplified
neuroblastoma cell lines [42] (Fig. 5a). Mirroring the effect
of MYCN overexpression in SY5Y-MYCN cells, the TGFB1
ITR was strongly inhibited in all MYCN-amplified cell lines
compared with MYCN single copy cells. Our publicly avail-
able datasets also revealed that, similar to RA, induction of
apoptosis by LiCl treatment (GSK3 inhibition) activated the
TGFB1 ITR (Fig. 5a). Therefore, both cellular phenotypes
associated with good outcome, i.e. differentiation and apop-
tosis, activated TGFB1 signalling.
We next examined MYCN ChIP-seq data [42] to deter-
mine if the inhibitory effect of MYCN on TGFB1 function-
ing (IPA ITR analysis) was achieved by MYCN binding to
TGFB1 targets or binding to components of the TGF-β sig-
nalling pathway. Both overexpressed and amplified MYCN
bound to the genes of a large number of TGFB1 targets
(IPA ITR analysis), with the number of genes bound in-
creasing with higher MYCN expression levels (Additional
file 1: Figure S5a). Similarly, a proportion of the genes
bound by MYCN have known SMAD regulatory elements
(Additional file 1: Figure S5b), as revealed by DiRE analysis
(See figure on previous page.)
Fig. 3 Gene ontology and signalling pathway analysis of the transcriptomic changes induced by RA and MYCN overexpression. a GO disease and
function terms associated with neuronal differentiation, generated by analysing the SY5Y-MYCN RNA-seq data with IPA. GO term activation/
inhibition levels are relative to those of the SY5Y-MYCN control cells. Full x-axis labels for the first, fourth and tenth bars, respectively, are:
‘differentiation of tumour cell lines’, ‘formation of plasma membrane projections’ and ‘differentiation of neuroblastoma cell lines’. b Top 15
differentially expressed signalling pathways (ranked by p value of overlap) between the 24-h 1-μM RA and 24-h 1-μl/ml DMSO vehicle control
SY5Y-MYCN RNA-seq treatments, as generated by IPA analysis. c Retinoic acid receptor (RAR) signalling pathway overlaid with genes differentially
expressed upon 24-h 1-μM RA treatment, as detected by RNA-seq. Pathway generated using IPA. Red shaded genes are upregulated by RA
compared to control cells, while green ones are downregulated by RA. Intensity of shading indicates the degree of up- or downregulation,
with deeper colours associated with higher levels of differential expression
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[81]. SMADs are the direct and prime transcriptional effec-
tors of TGF-β signalling [82, 83]. In addition, genes bound
by MYCN in KCNR cells were enriched for the TGF-β
signalling pathway, as revealed by IPA (pathway analysis,
p-value of overlap = 1.56E-02, ratio of overlap = 0.218), with
19 genes that encode components of the pathway being
a
c
d
b
Fig. 4 RA and MYCN overexpression drive opposing activation dynamics of their downstream transcriptional regulators. a Activation/inhibition score
of the RA inferred transcriptional regulator (ITR) in SY5Y-MYCN cells across the treatment groups. These values are generated, using IPA, from the
SY5Y-MYCN RNA-seq data. Activation/inhibition values are relative to the RA activity levels of the SY5Y-MYCN control cells. The total number of DE
genes used to call the differential activity of the ITR and the p value of overlap are shown within each bar. b Top 15 ITRs (ranked by p value of overlap)
from the SY5Y-MYCN RNA-seq data for each of the treatment groups compared with the DMSO vehicle control, as generated by IPA analysis. c
Protein–protein interaction map of the top 100 ITRs governing the genes differentially expressed between the 24-h 1-μM RA and 24-h DMSO vehicle
control treatments in SY5Y-MYCN cells. The protein interaction map of previously known connections between these proteins was generated with the
String database. Note that only protein ITRs are shown; miRNAs and drug compounds are excluded. d Activation/inhibition scores of selected ITRs
which were differentially activated between the RA and MYCN overexpression treatments. The scores were generated, using IPA, from the SY5Y-MYCN
RNA-seq data. Activation/inhibition values are relative to the ITR activity levels of the SY5Y-MYCN control cells
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genomically bound by MYCN (Additional file 1: Figure
S5c). TGF-β signalling pathway components were also
bound by MYCN in KCN (17 genes) and 48-h Dox-
induced SY5Y-MYCN (15 genes).
These results identified TGFB1 as a key regulator of
RA-mediated differentiation, which is differentially acti-
vated in a MYCN context-dependent manner, being sup-
pressed in MYCN-overexpressing and amplified cell
lines. Therefore, we next examined if RA treatment and
MYCN overexpression could modulate TGFB1 gene ex-
pression. MYCN overexpression modestly but signifi-
cantly reduced TGFB1 mRNA levels compared to RA-
only treated cells (t-tests, MYCN versus RA p value =
0.0076, RA versus co-treatment [MYCN and RA] p
value = 0.0010; Fig. 5b). In line with the MYCN overex-
pression results, three of the four MYCN-amplified cell
lines had lower TGFB1 mRNA expression than SY5Y
cells which are MYCN single-copy, with expression of
TGFB1 in KCNR cells being almost absent (Fig. 5c). The
inhibitory effect of MYCN upon TGFB1 mRNA expres-
sion was not rescued by RA treatment (Fig. 5b), suggest-
ing a novel mechanism through which MYCN can
inhibit RA-mediated neuronal differentiation.
While RA did not rescue the effect of MYCN overex-
pression on TGFB1 mRNA levels, it partially rescued
TGFB1 signalling, as revealed by the ITR analysis
(Fig. 5a). Additionally, the inhibitory effects of MYCN
on TGFB1 functioning in the other cell lines (Fig. 5a)
did not always correlate directly to TGFB1 mRNA ex-
pression levels (Fig. 5c), suggesting further levels of
cross-talk. Therefore, to further probe the functional re-
lationship between TFGB1 and MYCN we next exam-
ined MYCN’s protein–protein interactions.
MYCN protein interacts with TGF-β signalling-associated
proteins
While RA slightly increased TGFB1 mRNA levels and
MYCN overexpression reduced them, these changes do
not fully account for the differences in TGFB1 activation
revealed by the ITR analysis. Therefore, to investigate add-
itional potential cross-talk between MYCN and TGF-β
signalling we performed MYCN interaction proteomics
using the same experimental conditions as for the RNA-
seq experiments: (i) 24-h DMSO (control); (ii) 24-h RA;
(iii) 24-h RA and 48-h Dox; and (iv) 48-h Dox. We per-
formed IPA ITR analysis on the proteins bound by MYCN
in all conditions, which revealed that 32 TGFB1-regulated
proteins had protein–protein interactions with MYCN
(Fig. 5d). Of these, only MYCN’s interaction with HDAC2
was previously known (present in the String database).
Fourteen of the 32 proteins were differentially bound to
MYCN when RA-only treatment was compared with the
RA and Dox co-treatment, with the majority of them
binding less strongly to MYCN in the MYCN overexpress-
ing sample (Fig. 5e). For 13 of the 14 differentially bound
proteins, the change in MYCN binding was not as a result
of altered transcriptional regulation (Additional file 1:
Figure S5d); rather, altered binding was likely mediated by
post-translational events. Interestingly, the one protein in
which altered transcriptional regulation may have contrib-
uted to its differential binding to MYCN protein, at least
partially, was the neuroblast differentiation-associated
protein AHNAK. AHNAK was differentially expressed at
the mRNA level, with opposing regulation by MYCN
overexpression and RA treatment (Fig. 2a; Additional file
1: Figure S5d). AHNAK was bound to MYCN in all condi-
tions, and has been described as a tumour suppressor that
can stimulate the growth suppressing functions of the
TGF-β pathway [84].
Taken together, our findings reveal cross-talk between
MYCN and the TGF-β pathway at several levels, including
the regulation of TGFB1 mRNA expression, the regulation
of TGFB1 target genes and pathway components, and pro-
tein–protein interactions between MYCN- and TGFB1-
regulated gene products. They also show that MYCN and
RA drive opposing functional regulation of TGFB1.
(See figure on previous page.)
Fig. 5 The TGFB1 transcriptional regulator is differentially activated by RA and MYCN overexpression and interacts with MYCN’s protein–protein
interaction network. a Activation/inhibition score of the TGB1 ITR in neuroblastoma cells across a range of conditions: group 1, upon MYCN
overexpression (SY5Y-MYCN cells); group 2, in amplified MYCN cell lines (KCN, Kelly, IMR32 and KCNR) compared with MYCN single copy cells
(SY5Y); group 3, IMR32 cells induced to undergo apoptosis by 24-h 28-mM LiCl treatment compared with control IMR32 cells. Values for each
group are relative to the TGFB1 activity levels of the relevant control cells, SY5Y-MYCN un-induced, SY5Y cells and untreated IMR32 cells,
respectively. These values were generated, using IPA, from RNA-seq data from both the present study and two of our previous publications
[42, 45]. b Levels of absolute gene expression of TGFB1 mRNA in each of the SY5Y-MYCN RNA-seq treatments. Expression is in read counts per
million adjusted by gene length in kilobases (CPMkb), with error bars denoting the standard deviation between replicates. P values above each
bar are from t-test comparisons of TGFB1 expression in that condition with RA-treated cells. c Levels of absolute gene expression of TGFB1 mRNA
across a panel of neuroblastoma cell lines. IMR32, Kelly, KCN and KCNR are lines with amplified MYCN, while SY5Y is a single copy MYCN cell line.
Cell line data were mined from paired-end RNA-seq [42]. Expression is in read counts per million adjusted by gene length in kilobases (CPMkb),
with error bars denoting the standard deviation between replicates. P values above each bar are from t-test comparisons of TGFB1 expression in
that cell line with SY5Y cells. d Protein–protein interaction map of known TGFB1 targets (regulated proteins) which were found to bind to MYCN
protein in the SY5Y-MYCN interaction proteomic dataset. The protein interaction map of previously known connections between these proteins
was generated with the String database. e TGFB1 target proteins which showed differential binding (SY5Y-MYCN interaction proteomics) to MYCN
protein when the RA-only treatment and the RA and Dox (MYCN overexpression) combination treatment were compared
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The ability of MYCN overexpression to inhibit the
normal RA-mediated activation of TGFB1 signalling, re-
vealed here, further underscores the importance of TGF-
β suppression in contributing to MYCN’s oncogenic
potential. We therefore further investigated associations
of TGF-β signalling genes and outcome in neuroblast-
oma tumour data and whether pharmaceutical modula-
tion of the TGF-β pathway can enhance the effectiveness
of RA treatment in MYCN-amplified cell lines.
Genes mediating TGF-β signalling activation in response
to the small molecule kartogenin are prognostic of
neuroblastoma patient outcome
Having identified a role for TGF-β signalling in MYCN’s
blocking of RA-mediated neuronal differentiation, we next
assessed whether this shared node of MYCN and RA sig-
nalling was amenable to therapeutic intervention. Karto-
genin (KGN) is a recently developed small molecule which
enhances the activation of TGF-β signalling through indir-
ectly regulating the activity of the SMAD transcriptional ef-
fectors [85, 86]. KGN has been shown to promote
chondrocyte differentiation in vitro and in vivo [85–87].
KGN also strongly upregulates the expression of TGFB1 it-
self [87]. KGN competitively binds filamin A (FLNA), thus
inhibiting it from interacting with core-binding factor β
subunit (CBFB) [85]. CBFB that is not bound by FLNA is
then free to translocate from the cytoplasm to the nucleus,
where it complexes with the RUNX-SMAD transcriptional
machinery and regulates target gene expression (Fig. 6a).
Interestingly, we showed that SMADs 1, 2 and 6 and
RUNX2 were genomically bound by amplified MYCN
(Additional file 1: Figure S5c) and there was a protein–pro-
tein interaction between MYCN and FLNA (Fig. 5d, e), re-
vealing further levels of cross-talk between TGF-β
signalling, KGN’s mode of action and oncogenic MYCN.
The RUNX developmental regulators have previously been
implicated in a variety of cancers [88]. Therefore, to exam-
ine whether the FLNA-CBFB-RUNX2-SMADs module is
associated with neuroblastoma tumour biology and patient
outcome, we examined the R2 neuroblastoma datasets
(used above; http://r2.amc.nl) for these genes. Low CBFB
and high FLNA (inhibitor of CBFB) mRNA expression was
associated with poor patient outcomes (Fig. 6b; Additional
file 1: Figure S6a, b). In line with the differential activation
of the TGFB1 ITR by RA and MYCN, the SMAD transcrip-
tional effectors of the pathway were also largely differen-
tially activated between the two conditions, with the
canonical SMADs being inhibited by MYCN overexpres-
sion (Fig. 6c). Interestingly, SMAD7, an antagonist of TGF-
β signalling, was activated by MYCN and inhibited by RA,
potentially revealing another mechanism through which
MYCN inhibits RA-mediated activation of TGFB signalling.
Accordingly, high SMAD7 mRNA expression was predict-
ive of poor patient outcomes (Fig. 6d). Additionally, a
number of the other SMAD genes were predictive of pa-
tient outcome, with high SMAD1 and SMAD2 expression
associated with good outcomes (Additional file 1: Figure
S6c), while RUNX3 showed a better survival prediction
than RUNX2 (Fig. 6b; Additional file 1: Figure S6a–c).
KGN shows differentiating potential for neuroblastoma
but does not overcome the amplified-MYCN-mediated
differentiation block
Having demonstrated cross-talk between MYCN and the
TGF-β signalling pathway, and having shown that pathway
components targeted by KGN are associated with neuro-
blastoma patient outcome, we next treated MYCN-
amplified IMR32 cells to determine their response to KGN
individually and in combination with RA. IMR32 cells are
less responsive to RA-mediated differentiation than MYCN
single-copy cells. Low dose KGN (0.1–5 μM) was almost as
effective at differentiating IMR32 cells as RA (Fig. 7a, b),
with all treatment groups being significantly different to un-
treated controls (p < 0.0001 for all groups versus controls).
It should be noted that MYCN-amplified IMR32 cells are
far more resistant to differentiation than MYCN single-copy
neuroblastoma cells (see Fig. 1a for comparison). Interest-
ingly, when given in combination with RA, none of the low
dose KGN (0.1–5 μM) treatments enhanced the differenti-
ating potential over that seen in RA-only treatments (t-test,
p = 0.226–0.982). High dose KGN (10 μM) had a signifi-
cantly different differentiation ratio to untreated cells (t-test,
p < 0.0001), but the extent of differentiation was less than
that seen in lower dose KGN treatments (0.1–5 μM KGN).
It was also able to partially inhibit the differentiating effects
of RA in the combination treatment compared with RA-
only treatment (t-test, p < 0.0001).
While both RA and KGN increased the differentiation
ratio of IMR32 cells, the combination of these compounds
did not act synergistically to overcome the differentiation
block imposed by amplified MYCN (Fig. 7a, b). However,
combination treatment of RA with a high dose of KGN
(10 μM) resulted in a large proportion of cells with an
apoptotic-like rounded appearance (Fig. 7a; Additional file
1: Figure S7a). These apoptotic-like cells were not in-
cluded in the calculation of the differentiation ratios due
to their complete lack of axons; only surviving cells were
measured. In order to further assess the effect of KGN on
neuroblastoma cells, we next assessed cell viability.
Combination treatment of KGN and RA specifically
reduces viability of MYCN-amplified cells, but not MYCN
single-copy cells
The viability of IMR32 cells was reduced in a dose-
dependent manner by KGN (Fig. 7c), though the effect was
relatively mild. Our analysis suggested that combination
treatment with these two compounds should provide an
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additive or synergistic effect. Despite RA having no effect
on cell viability, RA treatment sensitised IMR32 cells to
KGN, with co-treated cells responding more strongly than
to each compound individually (Fig. 7a, c). Combination
treatment of 20 μM KGN and 1 μM RA strongly reduced
cell viability (t-test, p = 1.0E-04; Fig. 7c). Combination treat-
ment significantly reduced cell viability compared with
20 μM KGN-only treatment (t-test, p = 8.4E-03). MYCN-
amplified KCNR cells also showed a strong reduction in cell
viability upon combination treatment (Additional file 1:
Figure S7b; t-test, p = 4.0E-03). Importantly, in line with the
omics analysis, KGN-RA combination treatments only re-
duced the viability of MYCN-amplified cells, without sig-
nificant effects on the viability of the MYCN single-copy
cell line SY5Y (untreated versus 20 μM KGN and 1 μM
RA; t-test, p = 0.4715; Fig. 7d). Combination treatment also
significantly reduced the cell viability of NBL-S cells
(Additional file 1: Figure S7c; untreated versus 20 μM KGN
and 1 μM RA; t-test, p = 1.0E-04), which although being
MYCN single copy have elevated levels of MYCN protein
due to an increased MYCN protein half-life [89].
While KGN and RA did not cooperate to further dif-
ferentiate IMR32 cells, they did cooperate to enhance
the apoptotic response to treatment. As part of the RA
neuronal differentiation programme, RA is known to
block proliferation and promote apoptosis of normal
neuronal precursors and low-risk neuroblastoma cells,
in addition to inducing the differentiating of surviving
cells [90–94]. Similarly, ITR analysis revealed that
TGFB1 was strongly activated when IMR32 cells were
induced to undergo apoptosis by LiCl treatment (Fig. 5a).
To further functionally confirm that TGFB1 is involved
in directing neuroblastoma cell fate in a MYCN-
dependant manner, we mined an RNAi knockdown
screen targeting the druggable genome in SY5Y-MYCN
cells [42]. TGFB1 was a top ITR (ranked third) of the
674 genes that strongly reduced SY5Y-MYCN cell viabil-
ity when knocked down (Additional file 1: Figure S7d),
confirming the functional role of TGFB1 in neuroblast-
oma cell fate and supporting its likely therapeutic poten-
tial. RA was also a high ranking (12th) ITR of these
viability-reducing genes (Additional file 1: Figure S7d).
While elevated MYCN levels can block the pro-apoptotic
effects of RA (Additional file 1: Figure S7e), our results
reveal that KGN can be used as a combination therapy to
promote MYCN-amplified neuroblastoma cell death. Thus,
RA and KGN combination treatments represent a novel
therapeutic option with potential for targeting high-risk
MYCN-amplified tumours.
Pharmacological inhibition of TGF-β signalling strongly
attenuates RA-mediated neuronal differentiation
To confirm the functional role of the MYCN-induced
inhibition of TGF-β signalling in promoting retinoid re-
sistance we next investigated whether pharmacological
inhibition of TGF-β signalling could attenuate RA-
mediated differentiation in the absence of MYCN over-
expression. We treated SY5Y-MYCN cells with RepSox,
a potent and selective inhibitor of TGF-β receptor 1
(TGFBR1) [95]. RepSox can successfully replace Sox2 in
reprogramming cells and its use alongside other repro-
gramming factors is efficient at generating induced
pluripotent stem cells [96]. RepSox did not reduce the
viability of SY5Y-MYCN cells (Fig. 7e; DMSO-control
versus 100 nM RepSox; t-test, p value = 0.2244). When
un-induced SY5Y-MYCN cells were treated with RA and
RepSox, RepSox blocked the differentiating effect of RA
so strongly (1 μM RA-only versus 25 nM RepSox and
1 μM RA; t-test, p value <0.0001.0E-04) as to maintain
the differentiation ratio near the same level as that seen
in control cells (Fig. 7f ). Taken together, our results re-
veal that TGF-β signalling inhibition, whether achieved
by MYCN overexpression or pharmacological treatment,
strongly contributes to resistance to retinoid-mediated
differentiation in neuroblastoma cells and that pharma-
cological activation of TGF-β signalling represents a
promising strategy to sensitising MYCN-amplified cells
to retinoid-mediated apoptosis.
Discussion
Retinoids are an important component of advanced neuro-
blastoma therapy, yet half of all patients treated with iso-
tretinoin (13-cis retinoic acid) still relapse and die [97].
Therefore, more effective combination therapies, with a
lower side effect profile, are required to improve outcomes
[97]. Our omic data enhance our understanding of RA and
MYCN’s antagonistic relationship, revealing the molecular
mechanisms through which MYCN inhibits normal RA-
(See figure on previous page.)
Fig. 6 The components of the TGF-β pathway targeted by the small molecule kartogenin are predictive of neuroblastoma patient outcome. a
Schematic of the SMAD-RUNX portion of the TGF-β signalling pathway, showing how it is targeted by kartogenin (KGN). KGN inhibits FLNA, a
negative regulator of the pathway, thereby activating SMAD-RUNX-dependent transcriptional regulation. This pathway is a modified version of
the TGF-β pathway described in IPA. b Kaplan–Meier survival curves showing the predictive strength of the expression levels of the RUNX3, FLNA
and CBFP mRNAs in neuroblastoma tumours on patient outcome. Plots generated using the Kocak [69] 649 neuroblastoma tumour dataset in the
R2: Genomics Analysis and Visualization Platform (http://r2.amc.nl). c Activation/inhibition score of the SMAD ITRs which were altered in SY5Y-
MYCN cells across the treatment groups. These values are generated, using IPA, from the SY5Y-MYCN RNA-seq data. Activation/inhibition values
are relative to the corresponding SMAD activity levels of the SY5Y-MYCN control cells. d Kaplan–Meier survival curves showing the predictive
strength of SMAD7 expression levels in neuroblastoma tumours on patient outcome. Plots generated as described for panel b
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mediated neuronal differentiation and suggesting novel
combination therapies. The gene-level analysis successfully
identified targets known to be involved in retinoid-induced
neuroblastoma differentiation, which bolsters confidence in
the novel genes identified. Known genes identified include
ASCL1, RET, LMO4, CYP26A1, DKK2 and ODC1 [8, 9,
63, 98–103], many of which have also previously been iden-
tified as MYCN target genes whose expression levels are
correlated to patient survival outcome. Here we show that
these genes are differentially regulated by RA and MYCN,
with MYCN overexpression preventing their normal tran-
scriptional response to RA in the co-treatment condition.
The global analysis revealed that many transcriptional
regulators had differential activity (activation/inhibition) in-
duced by RA and MYCN overexpression. These regulators
included expected differentiation-associated ligands and
receptors such as NGF, BDNF, PDGF, RET [52, 104–106]
and RA itself, which provides further confirmation of our
analysis approach. Additionally, three regulators, Wnt, β-
estradiol and MAPK, which we recently independently
identified as being key components of the amplified-MYCN
signalling network [42, 71] with a role in neuroblastoma
differentiation, were shown here to be differentially acti-
vated by RA and MYCN overexpression. We recently dem-
onstrated that targeting each of these pathways altered
MYCN-amplified neuroblastoma viability and differenti-
ation and that co-treatment with RA had additive or syner-
gistic effects [42, 71], suggesting that such combination
therapies could be useful to treat MYCN-amplified neuro-
blastoma. MAPK (MEK) has also previously been linked to
MYCN-independent NF1-mediated RA resistance, and
MEK inhibition combined with RA treatment was pro-
posed as a potential strategy to treat NF1-deficient neuro-
blastomas [36]. MAPK inhibition and RA co-treatment has
recently been confirmed to synergistically reduce neuro-
blastoma tumour growth in vivo using zebrafish models
[107]. Similar to other genes identified in our analysis, the
neurotrophin receptor TrkB (NTRK2) and the Wnt, β-
estradiol and MAPK signalling pathways have all been
shown to have a strong correlation with poor prognosis in
neuroblastoma [42, 71, 108, 109]. Furthermore, MAPK and
Wnt-associated genes (including LEF1) have been shown to
be recurrently mutated in relapsed neuroblastoma [108,
110]. The emergence of the above molecules and pathways
in the present RA-mediated neuroblastoma differentiation
study further confirms their therapeutic potential.
By studying downstream signalling through the combin-
ation of transcriptomics and computational-inference of driv-
ing regulators, rather than genetic triggers (such as mutations
and epigenetic modifications), our approach can identify a
large range of relevant transcriptional regulators, including
epigenetic ones. Our approach provides a powerful tool for
precision oncology by identifying functional changes in
signalling networks that drive malignancies but may be the
result of different or combinatorial (epi)genetic events that
are often difficult to interpret in their own right not primarily
driven by somatic mutations, such as [38]. Given the paucity
of somatic mutations in paediatric cancers, including neuro-
blastoma [3, 38], it is likely that altered epigenetic regulation
can contribute to the widespread resistance to retinoid ther-
apy. For instance, it has been shown that epigenetic regula-
tion of the RARA gene (promoter methylation) can block the
subsequent differentiation of neuronal precursor cells [37].
Indeed, MYCN is known to interact with the epigenetic ma-
chinery [111, 112]. Our results revealed differentially activated
epigenetic regulators, including HDACs and BRD4, thus con-
firming the recently identified role for HDACs [8, 73–75] in
neuroblastoma responsiveness to RA. Retinoids were also the
top hits in a small molecule library screen for compounds
which enhanced HDAC inhibitor-mediated neuroblastoma
differentiation in vitro and xenograft regression in vivo [74].
Consistent with these results, our data reveal that RA inhibits
HDAC functioning while MYCN overexpression activates it.
It is interesting to note that RA itself was a top ITR of the
MYCN interaction partners in all three conditions (RA only,
Dox only, and RA and Dox). RA was a top ITR when all of
the MYCN-bound proteins were considered (p value of over-
lap range 1.23E-16 to 1.81E-16), but also when only those
(See figure on previous page.)
Fig. 7 Kartogenin and retinoic acid cooperate to reduce the viability of MYCN-amplified neuroblastoma cells. a Imaging of IMR32 cells treated for
3 days singly with 1 μM RA or 10 μM KGN, or a combination of both. All panels are imaged at 40× magnification. b The differentiation ratio of IMR32
cells treated for 3 days with individual agents (KGN or RA) or combination treatments (KGN and RA). The images from three biological replicates were
pooled and then measurements of individual cells were made using ImageJ v1.44p (http://imagej.nih.gov/ij). The range of measured cells (N) per
treatment group is 177–352. The differentiation ratio of each cell was calculated by dividing the length of its longest axon by the cell’s width. All
treatment groups are significantly different (with a p value <0.0001) to the untreated control cells. c, d Cell viability analysis of MYCN-amplified IMR32
(c) or single-copy MYCN parental SY5Y (d) cells treated for 72 h with KGN and RA, either individually or in combination, as detected by MTS assay.
Viability is set relative to that of the respective control untreated cells (IMR32 or SY5Y), with error bars denoting the standard deviation between
replicates. e Cell viability analysis of un-induced SY5Y-MYCN cells treated for 72 h with the TGF-βR1 inhibitor RepSox, as detected by MTS assay.
Viability is set relative to that of the respective DMSO vehicle-control cells, with error bars denoting the standard deviation between replicates. f The
differentiation ratio of un-induced (no Dox) SY5Y-MYCN cells treated for 3 days with RA-only or RA and RepSox combination treatment. The images
from three biological replicates were pooled and then measurements of individual cells were made using ImageJ v1.44p (http://imagej.nih.gov/ij).
The range of measured cells (N) per treatment group is 135–151. The differentiation ratio of each cell was calculated by dividing the length of its
longest axon by the cell’s width. P values (t-test) of each treatment group compared with the DMSO-vehicle controls are shown above each box
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proteins were considered which were differentially bound be-
tween conditions (p value of overlap range 4.28E-11 to
3.86E-12). These results suggest that in addition to altering
transcription of MYCN, RA transcriptionally regulates a large
number of MYCN’s interacting proteins, potentially re-wiring
MYCN’s interaction network.
A key differentially activated regulator was TGFB1, a lig-
and of the TGF-β signalling pathway. We identified MYCN-
RA-TGF-β cross-talk at several molecular levels, including
MYCN’s genomic binding, transcriptional activities and pro-
tein–protein interactome. TGFB1 was previously shown to
be induced by RA in RA-responsive neuroblastoma cell lines
[113]. Our data show that TGFB1’s effect as a transcriptional
regulator was strongly inhibited by MYCN overexpression or
amplification and strongly activated by RA. Interestingly,
MYCN’s effect on TGFB1 activity was dominant, with
TGFB1 being repressed in RA treated cells with MYCN
overexpression. We found that MYCN overexpression alters
TGFB1 functioning, not just by transcriptionally regulating
TGFB1 mRNA but also through protein–protein interac-
tions with a number of TGF-β signalling-associated proteins.
TGF-β signalling has previously been linked to adult
neurogenesis [114, 115], FGF2-mediated neuroblastoma
differentiation [116], and neuroblastoma cell invasiveness
[117]. While TGF-β can promote tumour progression in a
number of adult cancers [118, 119], we show that in neuro-
blastoma TGF-β is inhibited by MYCN overexpression and
MYCN amplification. We also show that TGF-β inhibition,
whether achieved through elevated MYCN levels or
pharmacological means, strongly contributes to retinoid
resistance. Additionally, the miR-17-92 microRNA cluster
has been shown to downregulate TGF-β signalling in
neuroblastoma and is a marker for poor survival [120].
Similarly, TGF-β receptor (type III) is reduced in high-stage
neuroblastoma, while increased TGF-β receptor (type II)
expression suppresses malignant neuroblastoma pheno-
types and induces differentiation [121, 122]. Our findings
combined with the known associations between TGF-β sig-
nalling and neuronal differentiation prompted us to investi-
gate the therapeutic potential of pharmaceutically activating
TGF-β signalling in neuroblastoma using KGN. As neuro-
blastoma cells can be induced to differentiate even in the
presence of a certain level of MYCN overexpression [31],
we investigated KGN-RA combination treatments in the
MYCN-amplified and RA-resistant IMR32 cell line. While
both compounds produced a modest increase in the differ-
entiation ratio of IMR32 cells, the combination treatment
primarily reduced the viability of MYCN-amplified cells
(IMR32 and KCNR cell lines). This therapeutic combin-
ation therefore demonstrates potential for the treatment of
high-risk MYCN-amplified patients. We also show that
KGN has differentiating potential in a neuronal lineage.
Our results suggest that KGN’s effectiveness in promoting
neuronal stem cells to differentiate should be investigated
further, particularly its effects in normal non-oncogenic
MYCN single-copy neuroblast cells. KGN may have
potential for neuronal regenerative medicine, similar to its
proposed uses for manipulating bone marrow stromal cells,
mesenchymal stem cells and patellar tendon stem cells for
tissue repair and regeneration [85, 86]. However, unlike in
bone marrow stromal cells and patellar tendon stem cells
where KGN also increases proliferation, KGN induced a
loss of viability in MYCN-amplified neuroblastoma cells,
showing therapeutic potential, an effect which was further
enhanced by co-treatment with RA. KGN is a first-
generation TGF-β signalling activator, with its ability to
promote mesenchymal stem cells into chondrocytes being
identified through an image-based high-throughput screen
[85]. Therefore, in addition to further pre-clinical studies of
RA-KGN combinations, it will be important to evaluate the
effectiveness of future iterations of small molecule TGF-β
signalling activators as potential neuroblastoma therapeu-
tics and enhancers of neuronal differentiation.
Conclusions
By applying genomic-level omics approaches to the signal-
ling networks regulating neuroblastoma differentiation and
stemness, we have determined the regulators involved in
the MYCN-mediated inhibition of neuroblastoma cell dif-
ferentiation. We have revealed a large network of intercon-
nected regulators governing neuronal differentiation, which
are differentially regulated by the pro-differentiation com-
pound RA and by differentiation inhibiting MYCN overex-
pression. A key differentially regulated pathway was TGF-β
signalling. TGF-β inhibition (RepSox) was sufficient to
strongly attenuate RA-mediated differentiation even in the
absence of MYCN overexpression. We have shown that co-
targeting of the retinoic acid and TGF-β pathways, through
RA and KGN (a small molecule TGF-β activator) combin-
ation treatment, strongly reduces MYCN-amplified RA-
resistant neuroblastoma cell viability.
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